[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 3,975.00 3,900.00 4,050.00 3,975.00 3,975.00 3,975.00 2,009 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.5 207

Bioventix Share Discussion Threads

Showing 1126 to 1146 of 1350 messages
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
DateSubjectAuthorDiscuss
18/12/2019
05:40
hxxps://maynardpaton.com/2019/12/17/bioventix-satisfactory-2019-results-reveal-yet-another-special-dividend-and-indicate-growth-during-2020-2025-depends-entirely-on-troponin/
carcosa
16/12/2019
10:48
Wrong board Sunningdale. Or are you posting that everywhere?
trident5
16/12/2019
10:39
Following on from my previous Open Orphans (ORPH) posts, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform. At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020
sunningdale1
28/11/2019
12:45
It's a couple months old but gives a useful overview of progress in beta amyloid blood tests: Https://www.alzforum.org/news/conference-coverage/are-av-blood-tests-ready-prime-time No mention of PRE Diagnostics. Assay precision will be important as, apparently, the difference between a positive and negative determination is as little as 10-15%. Some very high costs/test being achieved. "When pressed, Shimadzu representatives allowed that they were currently selling their service in Japan at a list price of about $1,000 per test and an actual negotiated rate of between $500 and $900." "C2N representatives told Alzforum that the current price for pharma and research use comes to roughly $700 per sample." Trials to assess clinical utility for the PRE/Bvxp test should be underway/starting shortly.
gsbmba99
26/11/2019
11:01
For those interested in other Pharma/bio stocks, Maurice Treacy, CCO of Open Orphan #ORPH reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform on the Vox Podcast. The interview starts at 10 minutes. hxxps://audioboom.com/posts/7433540-nuformix-open-orphan-zoetic-international-and-live-company-group
sunningdale1
22/11/2019
11:07
An interesting response to yesterday's research from a professor of interventional cardiology. Https://twitter.com/NickCurzen/status/1197546513221718019 "Fascinating result.... a much better use for troponin than diagnosing acute mi.... biomarker for lifespan?" Judging by the "likes", he isn't the only academic who thinks this. Applications for troponin beyond A&E could lead to a larger market opportunity for the Siemens test.
gsbmba99
21/11/2019
12:08
New research from ICL in BMJ on troponin - Https://www.bmj.com/content/367/bmj.l6055 with ICL article Https://www.imperial.ac.uk/news/194029/small-rise-heart-attack-protein-linked/ "A positive troponin result is therefore highly clinically meaningful, regardless of age, with the excess mortality associated with a raised troponin level being heavily concentrated in the first few weeks." "They also found that even when doctors do not think the primary problem is a heart attack, the presence of a raised troponin in the blood signifies an increased risk of death. Therefore, the troponin result provides meaningful information in all age groups, regardless of the underlying problem."
gsbmba99
20/11/2019
08:20
Liontrust increased from 7.68% to 10.16% Makes a change.
11_percent
09/11/2019
15:00
That's a fair point gnnmartin. I could extend that logic further though - assume the test shows a lack of vitamin D, and it is fixable by sunlight exposure rather than supplementation. Unfortunately, fixing with sunlight exposure is not always so easy - or even possible [he says, gazing out of the window onto a particularly gloomy UK scene]. So why even bother doing the test, if what it shows can't be easily remedied with a handful of pills? Cheers.
spann_703
09/11/2019
13:09
I read the article. It postulates that what is bad for health is not lack of vitamin D, but lack of sunlight. My first reaction was that this would be bad news for BVXP, but on reflection I am less concerned. Lack of vitamin D may not be an indicator for vitamin D supplements, but it remains an excellent indicator of insufficient exposure to sunlight.
gnnmartin
09/11/2019
11:46
spann_703, thank you. I enjoyed reading the article
piedro
09/11/2019
10:27
Piedro, I posted this article on the issue a short while back which you may find interesting: https://bit.ly/2RJnDzP IMO the evidence that supplementing with Vitamin D is beneficial is sketchy at best. You will have to form your own judgement as to the potential impact to Bioventix - given the revenue split my opinion is that it has to be a concern. Boros10 earlier made the point that a change in thinking on Vitamin D is unlikely to happen quickly, but given the information age we live in it's a view I don't share.
spann_703
09/11/2019
10:00
Seems to be saying that our assumptions that bad stuff happens if you're vitamin D deficient was wrong. After bad things happen you can become vitamin D deficient. Not the first time this idea has been aired.
trident5
09/11/2019
09:22
Could someone knowledgeable comment on this article and if it has any relevance to BVXP November 8, 2019 Vitamin D and Health Outcomes Then Came the Randomized Clinical Trials Anika Lucas, MD1; Myles Wolf, MD, MMSc1,2 https://tinyurl.com/yxpac8xu - TIA
piedro
29/10/2019
21:28
Your IQ test?
stepone68
29/10/2019
21:13
Awful results recently
albanyvillas
29/10/2019
12:55
For those that were interested in Open Orph (no worries if you're not, this is a shameless plug) the companies CCO Maurice Treacy is holding a live webinar on tomorrow 30th at 19:00 (UK time) hxxps://vtm.clickmeeting.com/orph The company has a four pronged strategy including a European health data collection platform - with patient clinical and genomic data. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive https://www.youtube.com/watch?v=eFvPcwjL-m4 ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.
sunningdale1
24/10/2019
12:16
18 quid John? You were saying 10 a couple of days ago. That's quite a turnaround. Are you a politician?
stepone68
24/10/2019
12:15
Span - I already did buy back in, unfortunately before the current price drop :-(
stepone68
24/10/2019
11:39
dead cat bounce the cat is dead long live the cat heading tio 18 quid
onjohn
24/10/2019
11:38
"An expert in chart analysis" Love it, they're like experts in astrology.
trident5
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
ADVFN Advertorial
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 04:14:43